Roth Capital Issues Pessimistic Forecast for CRDL Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Roth Capital lowered their FY2024 earnings per share estimates for Cardiol Therapeutics in a research report issued on Tuesday, November 19th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings per share of ($0.36) for the year, down from their prior estimate of ($0.32). The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.36) per share. Roth Capital also issued estimates for Cardiol Therapeutics' Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.36) EPS.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a research note on Wednesday. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Cardiol Therapeutics has a consensus rating of "Buy" and an average price target of $8.75.

Cardiol Therapeutics Stock Performance

NASDAQ CRDL opened at $1.56 on Thursday. The company has a market cap of $127.30 million, a P/E ratio of -4.23 and a beta of 0.91. The company has a fifty day simple moving average of $1.98 and a 200 day simple moving average of $2.09. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.01. Cardiol Therapeutics has a 12-month low of $0.79 and a 12-month high of $3.12.

Institutional Investors Weigh In On Cardiol Therapeutics

Institutional investors have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC purchased a new position in Cardiol Therapeutics during the 3rd quarter worth $27,000. Townsquare Capital LLC bought a new position in shares of Cardiol Therapeutics during the third quarter valued at about $27,000. Jane Street Group LLC purchased a new position in Cardiol Therapeutics during the third quarter worth about $29,000. Lion Street Advisors LLC grew its position in Cardiol Therapeutics by 7.9% in the 3rd quarter. Lion Street Advisors LLC now owns 273,281 shares of the company's stock worth $544,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft purchased a new stake in Cardiol Therapeutics in the 2nd quarter valued at about $59,000. Institutional investors own 12.49% of the company's stock.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.